Abstract
The analysis report aims to evaluate Pfizer financial performance in the last three years to provide a comprehensive analysis for stakeholders. Pfizer is a leading global biopharmaceutical giant with operations across the world. Pfizer put Research and Development at the core of business development, and owns range of exclusive patents in some key diseases area. In 2022, Pfizer generated 95% increase in revenue due to the excess demand of Comirnaty and other product categories. The skyrocketing revenue brings positive surplus to the cashflow, profitability and return ratios. In addition, business operations have improved in relation to inventory managements and turnover ratios, which are driven by corporate strategy and increasing demands. However, stepping into post pandemic times, the key business challenge for Pfizer is how to maintain growth in product sales since some of the key patent protection would be expired in the near future and the health sector is becoming more intensive and competitive.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
